Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
@article{TLCR78148, author = {Qiuyan Zhu and Ronghua Ni and Xin Guan}, title = {Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China}, journal = {Translational Lung Cancer Research}, volume = {12}, number = {8}, year = {2023}, keywords = {}, abstract = {}, issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/78148} }